Margin surge, revenue plateau, GPL recovery unproven

Verified: 26.5% YoY reported; volume +21-22%, price -1-2%, forex +7%

Q1 declined 52.6%; management cites inventory rationalization at large customer (50+ products); H2 historically stronger; confidence based on order pipeline conversation, not yet materialized

60.2% achieved; driven by product mix, new launches, RM pass-through partially. MD states margins will not 'drop off' but launches 'not fully fructified', second-gen process in reserve

Guidance implies 56-88% acceleration in growth rate; Q1 does not corroborate, showing slowing from prior quarters. GPL strength and non-GPL sustained launches required to deliver.

Q1 actual 36.6%; MD states 34% possible in steady-state if war/RM don't worsen. CFO notes margins will blend lower as GPL returns in H2, offset by CDMO + new launches

Prior call (FY26): reaffirmed high-single-digit growth, FY28 double-digit. Current: FY27 10-12% (materially higher than high-single-digit trajectory).

Prior: 30-32% range (upgraded from 28-30%). Current: 30-32% maintained; MD notes could reach 34% but conservative due to war/RM risk.

Solapur 'slight delay', now early Q3 FY27 vs earlier plan. Phase 3 deprioritised (under-absorption risk if rushed). Ankleshwar & Dahej expansions on track.

60% sustainable; launches still opening new markets, second-gen processes ready to defend margins. Operational efficiency is incremental and will continue.

Yes, could guide to 34%, but war/RM pricing volatility keeps conservative. Company has track record of conservative guidance and delivering upside.

Old, large customer; >50 products supplied; Q1 is not indicative; worst case is flat growth. Order pipeline and product diversity support recovery.

Patent expirations end calendar 2027 (FY28); 4-5 year runway thereafter. Launches start slightly earlier for customer prep.

Yes.

Net consumption favorable; wide product basket mitigates. Introduced membrane-based technology; can improve recovery by 5-10%. Not a silver bullet.

On track.

Get launches right (ongoing momentum). Solapur Phase 1 operational by Diwali; FDA inspection within 1 year post-op (big milestone for 3-4 year runway). Compliance track record good; light audit year (FDA, VAI Ankleshwar, NAI Dahej already done). Market patent expiry asynchrony driving launch volume.

Margin targets confident (32% base, 34% possible steady-state). RM costs monitored daily; passing to customers. Cash robust, receivables timely, no defaults. Inventory build intentional (buffer against RM price swings). Rupee depreciation beneficial (net exporter). Well-positioned.

Constant-currency growth 20%. Volume 21-22%, price decline 1-2%. Forex +7%.

Solapur Phase 1 & 1.1 on track, early Q3. Phase 3 deprioritised to avoid under-absorption; focus on Ankleshwar & Dahej brownfield expansions (on track, 160KL + 110KL). Solapur will be loaded with large-volume intermediates + backward integration block once operational; ROW business parked ~1 year.

Target steady-state ~4%. API-focused (new API growth, second-gen processes, specialty CDMO support). PAT will continue to be good; pipeline-driven growth offsets.

Capacity not a challenge; facilities top-tier. Not interested in capacity M&A. Pipelines of interest only if different platform/synergistic (1+1=3 or 4, not 2). Lateral expansion via 'API plus' (more from existing + new portfolio).

7 active projects under discussion; 5 generating current revenue. Discussions ongoing (lifecycle management, specialty focus). 1-1.5 year to project fruition. CDMO expected to grow faster than overall business given ₹160-170 Cr current run-rate and new projects kicking in H2. Can't quantify.

CDMO does add to margins, but volume small. Overall margin growth mix of CDMO + new API launches, not CDMO-driven alone.

Implies 56-88% acceleration from Q1's 6.4% base. Backed by non-GPL momentum (26.5%), GPL recovery (flat FY27 vs -52.6% Q1), and new launches. Requires GPL H2 bounce and sustained non-GPL traction.

Conservative base (30%) cites war/RM cost risk. MD confirms 34% possible steady-state if macro stabilizes. Q1 36.6% demonstrates capability; expected blend-down as GPL returns (lower margin).

Backed by launches (not fully fructified), operational efficiency (incremental), and second-gen process reserve. RM pass-through ongoing but limited.

Solapur Phase 1 & 1.1 (early Q3), Ankleshwar & Dahej brownfield expansions (on schedule), Taloja R&D center (construction begun). Phase 3 Solapur deferred to avoid under-absorption.

GPL revenue (~₹200-240 Cr implied) concentrated in single large, old customer supplying 50+ products. Q1 -52.6% YoY decline attributed to 'inventory rationalization'. Management confidence in FY27 flat growth unproven.

Solvents and KSM prices rising. Limited customer pass-through. CFO monitoring 'almost daily' but prices not fully recoverable across customer base.

Solapur 'slight delay', now early Q3 FY27 (vs original plan). Phase 3 deprioritised. Ankleshwar & Dahej expansions on track, but timing slippage could constrain capacity growth.

Q1 revenue growth 6.4% YoY, down from prior quarter run-rate. FY27 guidance of 10-12% implies 56-88% acceleration; credibility depends on GPL recovery (unproven) and sustained non-GPL traction (26.5% growth already achieved).

7 CDMO projects under discussion, 2 expected to close early H2 FY27 and contribute to acceleration. Timing/value not disclosed; slippage would impact FY27 growth target.